ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.69
−2.31%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.34x
- Price / sales
- 125.84x
- Price / cash flow
- -5.71x
Enterprise value
- Enterprise value
- $321.6M
- EV / sales
- 69.32x
- EV / EBITDA
- -2.11x
- EV / EBIT
- -1.78x
- Market cap
- $583.9M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026